Lutzky Jose
Melanoma Program, Division of Hematology/Oncology, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA.
Semin Cutan Med Surg. 2010 Dec;29(4):249-57. doi: 10.1016/j.sder.2010.10.006.
During the past 3 decades, the incidence, morbidity, and mortality of malignant melanoma have increased dramatically. Advanced melanoma has remained a disease that is for the most part incurable and has challenged all therapeutic efforts to make a dent in its natural history. Recent advances in the understanding of the molecular alterations in melanoma and in the immunologic mechanisms playing a role in this malignancy have brought hope that significant progress can be achieved, as evidenced by early encouraging clinical data. This review will summarize these recent developments and their impact on current clinical practice.
在过去的30年里，恶性黑色素瘤的发病率、患病率和死亡率急剧上升。晚期黑色素瘤仍然是一种大多无法治愈的疾病，对所有旨在改变其自然病程的治疗努力构成了挑战。对黑色素瘤分子改变以及在这种恶性肿瘤中起作用的免疫机制的最新认识进展带来了希望，即可以取得重大进展，早期令人鼓舞的临床数据证明了这一点。本综述将总结这些最新进展及其对当前临床实践的影响。
